In a parallel manner, exposure to docetaxel decreases prostate cancer cells’ mitosis rate, but increases motility, lowers E-cadherin expression, increases MMP-9 and changes morphology typical of EMT. This evidence concerns the gene CDH1 and prostate carcinoma.